isis pharmaceuticals inc
(ISIS:Consolidated Issue Listed on NASDAQ Global Select )
C. Frank Bennett BSc, Ph.D.
Senior Vice President of Antisense Research, Isis Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 3 different industries.|
As of Fiscal Year 2013
Dr. C. Frank Bennett, BSc, Ph.D. has been Senior Vice President of Antisense Research at Isis Pharmaceuticals, Inc. since January 01, 2006. Dr. Bennett served as Senior Vice President of Antisense Research of Isis Pharmaceuticals, Inc. since January 2006. Dr. Bennett is one of the founding members of Isis. He is involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory and ...
2855 Gazelle CourtPhone: 760-931-9200
Carlsbad, California 92010
Board Members Memberships*
Former Director and Member of the Scientific Advisory Board
Baylor College of Medicine
University of New Mexico
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Ron Cohen M.D.||Founder, Chief Executive Officer, President and Director|
Acorda Therapeutics, Inc.
|James A. Schoeneck||Chief Executive Officer, President and Director|
|Stephen R. Davis J.D.||Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President and Chief Business Officer|
ACADIA Pharmaceuticals Inc.
|Marc D. Beer||Chief Executive Officer and Director|
Aegerion Pharmaceuticals, Inc.
|Kleanthis G. Xanthopoulos Ph.D.||Chief Executive Officer, President, Principal Financial & Accounting Officer and Director|
Regulus Therapeutics Inc.
|$600.0K||Compensation as of Fiscal Year 2013.|